{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:19:51Z","timestamp":1792757991212,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32360185"],"award-info":[{"award-number":["32360185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017438","name":"Government of Xinjiang Uygur Autonomous Region of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008845","name":"Xinjiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110042","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:55:56Z","timestamp":1780012556000},"page":"110042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Recent progress of PROTACs in cancer immunotherapy"],"prefix":"10.1016","volume":"180","author":[{"given":"Peng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110042_bb0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0010","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110042_bb0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0025","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110042_bb0030","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110042_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0040","article-title":"Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study","volume":"15","author":"Shchelokov","year":"2023","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.bioorg.2026.110042_bb0045","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1120","article-title":"ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER plus \/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: phase 1b cohort (part C) of a phase 1\/2 study","volume":"40","author":"Hamilton","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/acschembio.4c00812","article-title":"Workflow for E3 Ligase Ligand Validation for PROTAC Development","volume":"20","author":"Miletic","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0070","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110042_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110042_bb0080","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","article-title":"The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron","volume":"610","author":"Ichikawa","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110042_bb0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0095","doi-asserted-by":"crossref","first-page":"13312","DOI":"10.1038\/ncomms13312","article-title":"Potent and selective chemical probe of hypoxic signalling downstream of HIF-\u03b1 hydroxylation via VHL inhibition","volume":"7","author":"Frost","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0100","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110042_bb0105","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110042_bb0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110042_bb0115","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1038\/s41467-023-44031-2","article-title":"Harnessing PROTAC technology to combat stress hormone receptor activation","volume":"14","author":"Gazorpak","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0120","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of Selective Small Molecule Degraders of BRAF-V600E","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0125","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.1021\/acs.jmedchem.4c00269","article-title":"Discovery of a series of orally bioavailable androgen receptor degraders for the treatment of prostate cancer","volume":"67","author":"Bagal","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0140","article-title":"Target protein localization and its impact on PROTAC-mediated degradation, Cell","volume":"29","author":"Simpson","year":"2022","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.07.006","article-title":"TMUB1 is an endoplasmic reticulum-resident escortase that promotes the p97-mediated extraction of membrane proteins for degradation","volume":"82","author":"Wang","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115911","article-title":"Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques","volume":"262","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-96704-2_4","article-title":"ESCRT and Membrane Protein Ubiquitination","volume":"57","author":"Migliano","year":"2018","journal-title":"Prog. Mol. Subcell. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012405","article-title":"PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy","volume":"13","author":"Liu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.110042_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110042_bb0175","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0180","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.110042_bb0185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2024.11.076","article-title":"PROTAC delivery in tumor immunotherapy: Where are we and where are we going?","volume":"378","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2026.110042_bb0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40259-025-00712-6","article-title":"Multispecific Antibodies Targeting PD-1\/PD-L1 in Cancer","volume":"39","author":"Chen","year":"2025","journal-title":"Biodrugs"},{"key":"10.1016\/j.bioorg.2026.110042_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110042_bb0200","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0205","doi-asserted-by":"crossref","first-page":"91-+","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110042_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117867","article-title":"Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1\/PD-L1 interaction","volume":"111","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0215","article-title":"A comprehensive review on current advances in peptide drug development and design","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency PD-1\/PD-L1 degradation induced by peptide-PROTAC in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110042_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405939","article-title":"Efficient Stereoselective Synthesis of Vepdegestrant (ARV-471) via Ruthenium-Catalyzed Asymmetric Hydrogenation","volume":"10","author":"Neerasa","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110042_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130428","article-title":"Design and validation of the first-in-class PROTACs for targeted degradation of the immune checkpoint LAG-3","volume":"130","author":"V\u00e1zquez","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110042_bb0235","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110042_bb0240","doi-asserted-by":"crossref","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0245","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational design and optimization of a potent IDO1 proteolysis targeting chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0250","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-025-07535-x","article-title":"Decoy-PROTAC for specific degradation of \"Undruggable\" STAT3 transcription factor","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110042_bb0260","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107016","article-title":"Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling","volume":"143","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0270","doi-asserted-by":"crossref","first-page":"18682","DOI":"10.1021\/acs.jmedchem.4c01906","article-title":"Discovery of novel PROTAC-based HPK1 degraders with high potency and selectivity for cancer immunotherapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117420","article-title":"Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic properties","volume":"289","author":"Lin","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116789","article-title":"Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo","volume":"277","author":"Mi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117027","article-title":"Development of hybrid aptamers-engineered PROTACs for degrading VEGF165 in both tumor- and vascular endothelial cells","volume":"281","author":"Feng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114821","article-title":"Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer","volume":"244","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0295","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1039\/C9CC08391J","article-title":"Degradation of intracellular TGF-\u03b21 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events","volume":"56","author":"Feng","year":"2020","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2026.110042_bb0300","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acs.jmedchem.2c01505","article-title":"Discovery of the first lactate dehydrogenase proteolysis targeting chimera degrader for the treatment of pancreatic cancer","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110281","article-title":"Degrading mutant IDH1 employing a PROTAC-based approach impairs STAT3 activation","volume":"765","author":"Dutta","year":"2025","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2026.110042_bb0310","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acssynbio.4c00109","article-title":"Degron-based bioPROTACs for controlling signaling in CAR T cells","volume":"13","author":"Kim","year":"2024","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0315","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.02.014","article-title":"Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs","volume":"188","author":"Jiang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0325","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0335","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2020.12.001","article-title":"Tryptophan and indole metabolism in immune regulation","volume":"70","author":"Fiore","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the Immune Response by the Aryl Hydrocarbon Receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.110042_bb0350","article-title":"The role of indoleamine 2, 3-dioxygenase 1 in regulating tumor microenvironment","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110042_bb0355","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110042_bb0360","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0365","doi-asserted-by":"crossref","first-page":"510-+","DOI":"10.1016\/j.celrep.2019.12.036","article-title":"FOXD3 regulates VISTA expression in melanoma","volume":"30","author":"Rosenbaum","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.110042_bb0370","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioorg.2026.110042_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189351","article-title":"VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis","volume":"1880","author":"Niu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110042_bb0380","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41422-025-01194-5","article-title":"Targeted destruction of VISTA boosts anti-tumor immunotherapy","volume":"35","author":"Chen","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.110042_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116958","article-title":"Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins","volume":"280","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110042_bb0395","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","article-title":"Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity","volume":"32","author":"Kennedy","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioorg.2026.110042_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.694145","article-title":"TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepatocellular carcinoma","volume":"11","author":"Bao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0405","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41423-023-01093-y","article-title":"The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8 T-cell immunity","volume":"20","author":"Yu","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41423-023-01105-x","article-title":"The E3 ubiquitin ligase TRAF6 controls CTLA-4 turnover and promotes T-cell-mediated antitumor immunity","volume":"21","author":"Jie","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091280","article-title":"STAT3, a Master Regulator of Anti-Tumor Immune Response","volume":"11","author":"R\u00e9b\u00e9","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110042_bb0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.chembiol.2023.02.005","article-title":"Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy","volume":"30","author":"Bonazzi","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in cancer and Its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0430","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110042_bb0435","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull's eye for targeted therapy?","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0440","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12964-025-02498-0","article-title":"Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer","volume":"23","author":"Chen","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110042_bb0445","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jaci.2022.06.021","article-title":"Allosteric inhibition of SHP2 rescues functional T-cell abnormalities in SAP deficiency","volume":"150","author":"Panchal","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0450","article-title":"Design, synthesis, and anticancer activity evaluation of the new SHP2 degraders","volume":"10","author":"Zhao","year":"2025","journal-title":"ChemSelect"},{"key":"10.1016\/j.bioorg.2026.110042_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117687","article-title":"Design, synthesis, anticancer activity evaluation and molecular dynamics study of pyrazine N-oxide-based SHP2 allosteric inhibitors","volume":"293","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0460","article-title":"Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioorg.2026.110042_bb0465","article-title":"HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0470","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117226","article-title":"Targeting hematopoietic progenitor kinase 1 (HPK1) for tumor immunotherapy: advances in small molecule inhibitors","volume":"242","author":"Tuersun","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0480","doi-asserted-by":"crossref","first-page":"15991","DOI":"10.1021\/acs.jmedchem.5c00970","article-title":"Discovery of a novel potent and orally efficacious PROTAC degrader of HPK1 for tumor immunotherapy","volume":"68","author":"Tong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110042_bb0485","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1122-8","article-title":"BTK: a two-faced effector in cancer and tumour suppression","volume":"9","author":"Rada","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110042_bb0490","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1151592","article-title":"A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bioorg.2026.110042_bb0495","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1038\/s41388-018-0668-3","article-title":"BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis","volume":"38","author":"Das","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110042_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252010968","article-title":"B cell lymphoma 6 (BCL6): a conserved regulator of immunity and beyond","volume":"25","author":"Liongue","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0505","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/1541-7786.MCR-22-0567","article-title":"B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers","volume":"20","author":"McLachlan","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110042_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400365","article-title":"IKZF2 degradation: it's time to take into account it when designing cereblon-based PROTACs","volume":"25","author":"Li","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.bioorg.2026.110042_bb0515","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1038\/s41467-025-58431-z","article-title":"Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110042_bb0520","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.tcb.2025.05.006","article-title":"The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth","volume":"36","author":"Grant","year":"2026","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bioorg.2026.110042_bb0525","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.tips.2023.08.013","article-title":"Targeted degradation of extracellular secreted and membrane proteins","volume":"44","author":"Chen","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0530","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156908","article-title":"The role of VEGF in cancer angiogenesis and tumorigenesis: insights for anti-VEGF therapy","volume":"189","author":"Shi","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.bioorg.2026.110042_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215925","article-title":"TGF-\u03b2 signaling networks in the tumor microenvironment","volume":"550","author":"Chan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110042_bb0545","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110042_bb0550","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110042_bb0555","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","article-title":"TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0560","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1039\/D3SC01874A","article-title":"Regulating tumor glycometabolism and the immune microenvironment by inhibiting lactate dehydrogenase with platinum(iv) complexes","volume":"14","author":"Jin","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0565","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101230","article-title":"IDH mutation subgroup status associates with intratumor heterogeneity and the tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"8","author":"Xiang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2026.110042_bb0575","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41590-024-01963-1","article-title":"Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1(+) progenitor CD8(+) T cells to improve immunotherapy","volume":"25","author":"Markowitz","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-024-01364-y","article-title":"Targeted degradation of membrane and extracellular proteins with LYTACs","volume":"46","author":"Li","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.110042_bb0585","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110042_bb0590","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4049\/jimmunol.2000252","article-title":"Proteolysis-targeting chimeras enhance T cell bispecific antibody-driven T cell activation and effector function through increased MHC class I antigen presentation in cancer cells","volume":"207","author":"Massafra","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0595","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41551-024-01285-5","article-title":"Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates","volume":"9","author":"Zhao","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioorg.2026.110042_bb0600","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioorg.2026.110042_bb0605","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110042_bb0610","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acssynbio.9b00476","article-title":"A chemical switch system to modulate chimeric antigen receptor T cell activity through proteolysis-targeting chimaera technology","volume":"9","author":"Lee","year":"2020","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.bioorg.2026.110042_bb0615","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","article-title":"Degraders upgraded: the rise of PROTACs in hematological malignancies","volume":"143","author":"Casan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110042_bb0620","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01560-z","article-title":"Tumour-specific bioorthogonal synthesis of proteolysis-targeting chimeras and nanoparticles boosts T cell activity","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioorg.2026.110042_bb0625","doi-asserted-by":"crossref","first-page":"18108","DOI":"10.1039\/D5CC03325J","article-title":"Click chemistry enables rapid development of potent sEH PROTACs using a direct-to-biology approach","volume":"61","author":"Sch\u00f6nfeld","year":"2025","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2026.110042_bb0630","article-title":"In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bioorg.2026.110042_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113719","article-title":"Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications","volume":"382","author":"Yu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2026.110042_bb0640","article-title":"Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600578X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600578X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:43:28Z","timestamp":1787676208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600578X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":128,"alternative-id":["S004520682600578X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110042","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress of PROTACs in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110042"}}